Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, January 13, 2021
bluebird bio announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly traded companies.
read more
Thursday, August 23, 2018
bluebird bio and Gritstone Oncology announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
read more
bluebird bio and Regeneron announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer.
read more
BlueTheory Clinical Trials, a clinical research network company headquartered in Boston, Massachusetts has been partnering with pharmaceutical and contract research organizations (CROs) to bring treatments and devices to the market since its ...
read more
Monday, February 01, 2016
Bristol-Myers Squibb Company and Pfizer have announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, ...
read more
Thursday, October 29, 2015
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes ...
read more
Medidata a provider of cloud-based solutions for clinical research in life sciences, has announced that Bristol-Myers Squibb has selected the Medidata Clinical Cloud® to help manage, monitor and analyze its clinical trials.
read more
Tuesday, October 20, 2020
Bora Pharmaceuticals announced its Chairman and CEO, Bobby Sheng, was unveiled as ‘CEO of the Year’ at the CPhI Pharma Awards 2020.
read more
In order to add to scientific and medical progress, Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug ...
read more
Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specializing in the development of innovative therapies for fibrosis, oncology and orphan diseases, have announced a new multi-year research and drug discovery collaboration and ...
read more
Tuesday, February 21, 2012
Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal ...
read more
Boehringer Ingelheim and Bridge Biotherapeutics announced they are entering into a new collaboration and license agreement with the goal of developing autotaxin inhibitor BBT-877.
read more
Boehringer Ingelheim announced today an agreement with Servier and its partner XOMA Corporation (Nasdaq: XOMA) to transfer XOMA’s technology and process for the commercial manufacture of gevokizumab, XOMA’s novel interleukin 1-beta (IL-1ß) allosteric...
read more
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center.
read more
Monday, February 03, 2020
Boehringer Ingelheim selected Docuvera to enable medical authors to build clinical and regulatory documents from pre-approved components of medical content.
read more